EU eCTD Submissions 2026: Key Updates from EMA
European regulatory environment is still kept changing, and the European Medicines Agency (EMA) has been proposing essential changes to the EU eCTD submissions. In the case of pharmaceutical and life sciences firms that focus on Europe, compliance is no longer a choice to make but a necessity to succeed in terms of timely approvals and penetrating the market.
Latest EMA Updates
In 2025, the EMA released EU Module 1 Specification v3.1.1 which is obligatory by the end of 2025. Accompanied with this, refresh Validation Criteria v8.2 imposes technical requirements which are more stringent. Such updates have a considerable effect on the dossier preparation, validation, and submission.
Also, the harmonised guidance provided by the EMA ensures that expectations related to submissions are harmonised among the EU member states, and it is easier, yet more technically complex, to coordinate centralised, decentralised, and mutual recognition processes by the companies.
Role of Other European Health Authorities
Beyond the EMA, national agencies such as:- MHRA (UK)
- BfArM (Germany)
- ANSM (France)
continue to align with EU eCTD standards while maintaining specific local requirements. This creates complexity in managing multi-country submissions.
How Masuu Global Helps
Masuu Global provides advanced eCTD software and regulatory support tailored for European submissions. Our solutions ensure:- Full compliance with EMA specifications (v3.1.1 and beyond)
- Automated validation aligned with latest criteria
- Seamless lifecycle management across multiple regions
As more companies are subjected to regulatory scrutiny conducted by EMA and other European governments, firms need to implement powerful systems and skills. Masuu Global helps organizations to be ahead of compliance change and shorten the submission timeline.